the prices charged a year ago. In the past year, the antibiotic amoxicillin, for example, has risen from 47p ($0.75) to £1.69 for a 250 mg pack of tablets. A 100 mg pack of thyroxine has gone up in price from 21p to £1.62, and a 40 mg pack of the diuretic frusemide (furosemide) costs £2.14, compared with 26p in September 1998.
Over the same period the number of generic drugs classified by the Department of Health as in short supply has increased from 30 to 190. In the case of these medicines, known as category D list drugs, doctors and pharmacists may prescribe and dispense more expensive brandname alternatives.
The rises could add £200m ($320m) to the NHS annual drugs bill if current trends continue, according to Labour MP for The Wrekin, Peter Bradley. He was alerted to the problem earlier this year by a local GP, Dr Chris Brown, and by Shropshire health officials, who have predicted a deficit of £1.5m in their county's drugs budget as a result of the increases.
The British Generic Manufacturers Association, which represents nearly three quarters of producers, blames various factors for the widening gap between demand and supply. It cited the closure by the Medicines Control Agency of a major generic drug manufacturer, Regent GM in west London, over concerns about possible product contamination.
Manufacturers were also still in the process of switching from bulk production to packs for patients, in line with a recent EU directive.
John Close, the association's chairman, said last week that there was "no artificial restriction of generics."
After meeting Mr Bradley on 21 October, the health minister Lord Hunt expressed the government's concern over the shortages and price jumps. He said: "The generics market is not controlled by the government. The normal situation of competition keeping prices down is evidently not working at the moment. A fundamental look at this whole issue is currently under way."
Mr Bradley later described the manufacturers' explanations for the problems as a "pretty wispy smokescreen."
He told the BMJ: "The upward trend in prices began before the closure of the Regent GM plant. A lot of doctors are suspicious that this is the drugs industry hitting back against government attempts to get better value for money from drug budgets."
Government orders inquiry as price of generic drugs soars
Judy Jones Malmesbury, Wiltshire
186, 218
Frusemide under the microscope: its price has gone up more than 700% in a year 15551
MICHAEL W DAVIDSON AT NHMFL/FLORIDA STATE UNIVERSITY
A team of scientists working at Amgen, a leading biotechnology company at Thousand Oaks, California, has succeeded in identifying two proteases believed to be responsible for the formation of amyloid plaques in the brains of patients with Alzheimer's disease.
Their report is published in the current issue of Science (1999;286:735-41) . Amyloid has been clearly implicated in the pathogenesis of Alzheimer's disease (BMJ 1998; 317:102) . The Amgen team found that the deposition of amyloid depended on the proteolytic cleavage of the amyloid precursor protein (APP) by two unknown proteaes-β secretase and γ secretase.
Amyloid is composed of aggregations of protein fragments called Aβ, a small piece of a much larger protein that protrudes from cells. β Secretase cuts the protein in two and is followed by γ secretase, which cleaves the resulting protein fragments, creating the Aβ protein (which ultimately becomes amyloid) and harmless protein debris.
Over the past two years, the team, led by Dr Martin Citron, has searched for the gene which directs cells to make β secretase.
Its report stated: "A transmembrane aspartic protease with all the known characteristics of β secretase was cloned and characterised. Overexpression of this protease, termed BACE (for β-site APP-cleaving enzyme) increased the amount of β secretase cleavage products, and these were cleaved exactly and only at known β secretase positions.
"Antisense inhibition of endogenous BACE messenger RNA decreased the amount of β secretase cleavage products, and purified BACE protein cleaved APP-derived substrates with the same sequence specificity as β secretase. Finally, the expression pattern and subcellular localization of BACE were consistent with that expected for β secretase."
The paper concluded that "future development of BACE inhibitors may prove beneficial for the treatment of Alzheimer's disease." The Amgen team's achievement is all the more significant, as other investigators over the past decade have failed to identify β secretase.
Dr Rudolph Tanzi, a professor of neurology at Harvard Medical School, in referring to protease inhibitors now used in the treatment of AIDS, said: "This is as exciting for Alzheimer's research as the HIV protease enzyme was for AIDS research." (See p 1155.)
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